keyword
MENU ▼
Read by QxMD icon Read
search

vaccine V114

keyword
https://read.qxmd.com/read/30689507/a-dose-ranging-study-of-2-different-formulations-of-15-valent-pneumococcal-conjugate-vaccine-pcv15-in-healthy-infants
#1
R Rupp, D Hurley, S Grayson, J Li, K Nolan, R D McFetridge, J Hartzel, C Abeygunawardana, M Winters, H Pujar, P Benner, L Musey
BACKGROUND: Two new formulations of an investigational 15-valent pneumococcal conjugate vaccine (PCV15-A and PCV15-B) were developed using 2 different protein-polysaccharide conjugation processes and evaluated in separate phase I/II studies (NCT02037984 [V114-004] and NCT02531373 [V114-005]) to assess optimal concentrations of pneumococcal polysaccharide (PnPs) and Aluminum Phosphate Adjuvant. METHODS: Various lots of PCV15-A and PCV15-B containing different concentrations of PnPs and/or adjuvant were compared to PCV13 in young adults and infants...
January 28, 2019: Human Vaccines & Immunotherapeutics
https://read.qxmd.com/read/30648919/safety-and-immunogenicity-of-15-valent-pneumococcal-conjugate-vaccine-pcv-15-compared-to-pcv-13-in-healthy-older-adults
#2
Helen L Stacey, Jeffrey Rosen, James T Peterson, Angela Williams-Diaz, Vanita Gakhar, Tina M Sterling, Camilo J Acosta, Katrina M Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J Smith, Hari Pujar, Luwy K Musey
BACKGROUND: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 additional serotypes (22F and 33F) were evaluated in adults ≥ 50 years (V114-006; NCT02547649). METHODS: A total of 690 subjects (230/arm) received a single dose of either PCV15 Formulation A, PCV15 Formulation B, or PCV13 and were followed for safety for 14 days postvaccination...
January 16, 2019: Human Vaccines & Immunotherapeutics
https://read.qxmd.com/read/30427749/safety-and-immunogenicity-of-15-valent-pneumococcal-conjugate-vaccine-compared-to-13-valent-pneumococcal-conjugate-vaccine-in-adults-%C3%A2-65-years-of-age-previously-vaccinated-with-23-valent-pneumococcal-polysaccharide-vaccine
#3
James T Peterson, Helen L Stacey, John E MacNair, Jianing Li, Jonathan S Hartzel, Tina M Sterling, Patrice Benner, Gretchen M Tamms, Luwy K Musey
BACKGROUND: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and reduced antibody titers in comparison to longer intervals. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) was evaluated in adults ≥ 65 years of age with prior history of PPV23 vaccination (V114-007; NCT02573181)...
November 14, 2018: Human Vaccines & Immunotherapeutics
https://read.qxmd.com/read/30244873/safety-and-immunogenicity-of-15-valent-pneumococcal-conjugate-vaccine-pcv15-in-healthy-infants
#4
David Greenberg, Patricia A Hoover, Timo Vesikari, Christopher Peltier, David C Hurley, Richard D McFetridge, Michael Dallas, Jonathan Hartzel, Rocio D Marchese, Beth-Ann G Coller, Jon E Stek, Chitrananda Abeygunawardana, Michael A Winters, John E MacNair, Narahari S Pujar, Luwy Musey
BACKGROUND: Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent PCV (PCV15) containing serotypes included in 13-valent PCV (PCV13) plus serotypes 22F and 33F were evaluated in infants (NCT01215188). METHODS: Infants received adjuvanted PCV15, nonadjuvanted PCV15, or PCV13 at 2, 4, 6, and 12-15 months of age...
September 20, 2018: Vaccine
https://read.qxmd.com/read/29559167/safety-and-immunogenicity-of-15-valent-pneumococcal-conjugate-vaccine-in-pneumococcal-vaccine-na%C3%A3-ve-adults-%C3%A2-50-years-of-age
#5
Susan J Ermlich, Charles P Andrews, Steven Folkerth, Richard Rupp, David Greenberg, Richard D McFetridge, Jonathan Hartzel, Rocio D Marchese, Jon E Stek, Chitrananda Abeygunawardana, Luwy K Musey
BACKGROUND: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 additional serotypes (22F and 33F) was evaluated in adults ≥50 years old (NCT01513551). METHODS: 691 adults received one dose of PCV15, PCV13, or 23-valent pneumococcal polysaccharide vaccine (PPV23) and were followed 14 days for safety...
March 17, 2018: Vaccine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"